A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Site 36, La Jolla, California +143 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Spotting and Managing Adult Repeated Traumas in the Brain
NCT07025317
Recruiting
Emerging evidence suggests that concussions (a type of mild traumatic brain injury; mTBIs) may cause chronic neurological disturbances with effects lasting beyond 20 years, changing brain structure and nearly doubling the risks of developing dementia into old age. Yet diagnoses remain notoriously difficult, gender differences are poorly understood, and negligible therapies exist to manage and treat these long-term effects. This project proposes using a combination of NeuroTracker (a promising s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/16/2025
Locations: Christie Lab, Victoria, British Columbia +2 locations
Conditions: Brain Injury Traumatic Mild
Register for Updates
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504
Recruiting
This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Bakersfield, California +51 locations
Conditions: Hepatitis B
Register for Updates
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
NCT07082543
Recruiting
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/16/2025
Locations: Children's Hospital and Research Center at Oakland, Oakland, California +30 locations
Conditions: Gangliosidoses, GM2, Gangliosidosis, GM1
Register for Updates
Phase 1 Crossover Study Evaluating the Safety, Tolerability, and Pharmacokinetics of KP001 in Healthy Adult Volunteers
NCT06963411
Recruiting
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of several KP001 dose regimens to identify a treatment regimen with a PK profile that safely meets or exceeds the PK profile of existing injected epinephrine products. The main questions it aims to answer are: * To evaluate any carryover effect with a 7-day washout of different dose regimens of KP001 in healthy adult volunteers. * To evaluate the safety, tolerability and PK of different dose regim... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/16/2025
Locations: Syneos HealthClinique Inc., Quebec City, Quebec
Conditions: Acute Allergic Reaction, Anaphylaxis
Register for Updates
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
NCT05692180
Recruiting
A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/16/2025
Locations: Research Site, Mobile, Alabama +86 locations
Conditions: Asthma
Register for Updates
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768
Recruiting
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/16/2025
Locations: Children's Hospital Los Angeles (CHLA), Los Angeles, California +34 locations
Conditions: Cholestatic Liver Disease (except ALGS, PFIC, PBC and PSC)
Register for Updates
Impact of Healthy Food Subsidies on Diet Quality and Food Security
NCT06992947
Recruiting
The British Columbia Farmers' Market Nutrition Coupon Program (FMNCP) provides lower-income households with coupons to purchase healthy foods at farmers' markets. This pragmatic randomized controlled trial (RCT) will examine the effectiveness and cost-effectiveness of two higher subsidies for healthy food ($54/weeek or $81/week), compared to the usual FMNCP healthy food subsidy ($27/week), on the diet quality (primary outcome), food insecurity, and other health-related outcomes of 276 parent-chi... Read More
Gender:
ALL
Ages:
Between 6 years and 64 years
Trial Updated:
07/16/2025
Locations: Participants recruited in 93 communities across British Columbia, Canada, Communities across BC, British Columbia
Conditions: Food Insecurity
Register for Updates
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894
Recruiting
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/16/2025
Locations: Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois +23 locations
Conditions: Generalized Myasthenia Gravis
Register for Updates
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443
Recruiting
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/16/2025
Locations: Allervie Clinical Research, Birmingham, Alabama +83 locations
Conditions: Moderate to Severe Asthma
Register for Updates
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
NCT05263934
Recruiting
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: GSK Investigational Site, Denver, Colorado +80 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis
Register for Updates
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
NCT06932458
Recruiting
Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%). For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: London Health Sciences Centre, London, Ontario
Conditions: Testicular Cancer
Register for Updates